Chemotherapy Market Forecast and Scope - 2031
The Chemotherapy Market is expected to register a CAGR of 8.2% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Indication (Colorectal Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Ovarian Cancer, Lymphoma, Prostate Cancer, Leukemia, others), Drug Class (Topoisomerase Inhibitors, Mitotic inhibitors, Antitumor antibiotic, Alkylating agents, others), Route of Administration (Subcutaneous, Intra-Muscular, Intravenous, Intravesicular, Intraventricular/Intrathecal, Topical, Oral, Intraperitoneal, others ). The report further presents analysis based on the DEnd User (Hospitals and Clinics, Specialty Centers, Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Chemotherapy Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Chemotherapy Market Segmentation
Indication- Colorectal Cancer
- Breast Cancer
- Lung Cancer
- Stomach Cancer
- Ovarian Cancer
- Lymphoma
- Prostate Cancer
- Leukemia
- others
- Topoisomerase Inhibitors
- Mitotic inhibitors
- Antitumor antibiotic
- Alkylating agents
- others
- Subcutaneous
- Intra-Muscular
- Intravenous
- Intravesicular
- Intraventricular/Intrathecal
- Topical
- Oral
- Intraperitoneal
- others
- Hospitals and Clinics
- Specialty Centers
- Others
- Hospitals and Clinics
- Specialty Centers
- Others
Strategic Insights
Chemotherapy Market Growth Drivers- Rising Incidence of Cancer: One of the major factor driving the chemotherapy market is the rising incidence of cancer across the world. The World Health Organization has estimated new cases of cancer to increase 60% within a period of two decades of time. By 2030, the number of new cases will reach 25 million per year, thereby increasing the chemotherapy treatment demand, which will expand the market.
- Advances in Targeted Therapies: Targeted therapy is chemotherapy that is targeted towards cancer cells without harming the non-cancerous cells. Advances in targeted therapies are thus creating more effective yet less toxic chemotherapies, which are being adopted more widely. Targeted therapy has been the breakthrough for oncologists; therefore, targeted or precision medicines must do better, more homogenous drugs which may result in more uniform efficiency of the patient. More potent and targeted chemotherapy agents will likely be discovered, as research continues to progress.
- Rising Adoption of Combination Therapy: Combination therapy is the adoption of multiple chemotherapy drugs or treatments that give better outputs as compared with the individual chemotherapy drugs or treatments. This growing trend for combination therapy through which various options of more effective treatments are offered to the patient, and is thus propelling the demand of this market ahead. In recent years, there has been realization of improved outcome and reduced side effects when using combination therapy in patients.
- Increasing demand for Immunotherapy: It is a type of cancer treatment aimed at assisting in controlling the spread of cancer cells through the body's immune system. Increasing demand for immunotherapy against different forms of cancer has been the primary growth factor for this market. Lung, breast, and colon cancer are among several cancers promising to be treated. More research will reveal that future treatments will be far more effective, further contributing to market growth.
- Digital Therapeutics enhances Patient Care: Digital therapeutics are technology-based treatments that have emerged as user-friendly ways to help patients manage their chemotherapy schedules. Over time, digital therapeutics have gradually become a tool in enhancing patient care outcomes and reducing side effects resulting from treatment. Digital therapeutics can be presented as the most convenient and easy way of life for chemotherapy treatment management by the patient. With increasing awareness by health care service providers about digital therapeutics, their adoption rate is bound to go higher, which in turn will boost market growth.
- Telemedicine is likely to be a growing Trend in Chemotherapy Delivery: According to the latest trends, telemedicine is changing the very mode of chemotherapy administration. Telemedicine has a better patient outcome and slashes healthcare costs by conducting remote consultations and monitoring the treatment process for patients. Telemedicine is changing the face of healthcare delivery to patients. Therefore, when telemedicine becomes a mainstream form of delivery, more effective and efficient delivery models shall come through, driving further growth in the market.
- Elaboration of existing therapies into new indications: While chemotherapy treatments are only indicated for a subset of cancers, there is substantial evidence that most of them work as well for other cancers. Further indication might represent an area of growth in the market. Extending indication for already marketed treatments increases the possibility of further market growth as more patients have access to appropriate therapy. Future expansion of indications of existing treatments is anticipated by future research and discovery of new uses, which will result in more extended indications of such treatments and further extended market growth.
- New treatment modalities: New modalities of treatment, such as nanotechnology-based treatments, might provide new avenues for further extension of markets. Such treatments based on nanotechnology hold much promise for better outcomes in patients and decreased side effects from the treatment itself. Further developments in new treatment modalities will only increase with time, and we may expect to witness even more novel solutions arising that drive market growth in this direction.
- Increased attention to patient-reported outcomes: The growing importance of chemotherapy treatment effectiveness lately has been in patient-reported outcomes. Focusing on these will help health professionals understand what and what the patients need as well as which patients would prefer. Patient-reported outcomes hold great promise for the enhancement of patient care, well based on better understanding of need and preferences for patients. The likely years to come would see an increased attention toward the field, considering more research and development activities in light of growing awareness of the importance of patient-reported outcomes among healthcare providers.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Chemotherapy Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Chemotherapy Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The chemotherapy market is estimated to grow with a CAGR of 8.2% from 2023 to 2031
Asia-Pacific region is likely to witness the fastest growth rate during the forecast period
The chemotherapy market majorly consists of players such as Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company among others.
Development of immunotherapies is likely to remain the key trend during the forecast period.
The market drivers include the increasing prevalence of cancer and rising geriatric population, which are driving the chemotherapy market.
North America dominated the chemotherapy market in 2023
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chemotherapy Market - By Indication
1.3.2 Chemotherapy Market - By Drug Class
1.3.3 Chemotherapy Market - By Route of Administration
1.3.4 Chemotherapy Market - By End User
1.3.5 Chemotherapy Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHEMOTHERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHEMOTHERAPY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CHEMOTHERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1. CHEMOTHERAPY - GLOBAL MARKET OVERVIEW
6.2. CHEMOTHERAPY - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CHEMOTHERAPY MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. COLORECTAL CANCER
7.3.1. Overview
7.3.2. Colorectal Cancer Market Forecast and Analysis
7.4. BREAST CANCER
7.4.1. Overview
7.4.2. Breast Cancer Market Forecast and Analysis
7.5. LUNG CANCER
7.5.1. Overview
7.5.2. Lung Cancer Market Forecast and Analysis
7.6. STOMACH CANCER
7.6.1. Overview
7.6.2. Stomach Cancer Market Forecast and Analysis
7.7. OVARIAN CANCER
7.7.1. Overview
7.7.2. Ovarian Cancer Market Forecast and Analysis
7.8. LYMPHOMA
7.8.1. Overview
7.8.2. Lymphoma Market Forecast and Analysis
7.9. PROSTATE CANCER
7.9.1. Overview
7.9.2. Prostate Cancer Market Forecast and Analysis
7.10. LEUKEMIA
7.10.1. Overview
7.10.2. Leukemia Market Forecast and Analysis
7.11. OTHERS
7.11.1. Overview
7.11.2. others Market Forecast and Analysis
8. CHEMOTHERAPY MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. TOPOISOMERASE INHIBITORS
8.3.1. Overview
8.3.2. Topoisomerase Inhibitors Market Forecast and Analysis
8.4. MITOTIC INHIBITORS
8.4.1. Overview
8.4.2. Mitotic inhibitors Market Forecast and Analysis
8.5. ANTITUMOR ANTIBIOTIC
8.5.1. Overview
8.5.2. Antitumor antibiotic Market Forecast and Analysis
8.6. ALKYLATING AGENTS
8.6.1. Overview
8.6.2. Alkylating agents Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. others Market Forecast and Analysis
9. CHEMOTHERAPY MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. SUBCUTANEOUS
9.3.1. Overview
9.3.2. Subcutaneous Market Forecast and Analysis
9.4. INTRA-MUSCULAR
9.4.1. Overview
9.4.2. Intra-Muscular Market Forecast and Analysis
9.5. INTRAVENOUS
9.5.1. Overview
9.5.2. Intravenous Market Forecast and Analysis
9.6. INTRAVESICULAR
9.6.1. Overview
9.6.2. Intravesicular Market Forecast and Analysis
9.7. INTRAVENTRICULAR/INTRATHECAL
9.7.1. Overview
9.7.2. Intraventricular/Intrathecal Market Forecast and Analysis
9.8. TOPICAL
9.8.1. Overview
9.8.2. Topical Market Forecast and Analysis
9.9. ORAL
9.9.1. Overview
9.9.2. Oral Market Forecast and Analysis
9.10. INTRAPERITONEAL
9.10.1. Overview
9.10.2. Intraperitoneal Market Forecast and Analysis
9.11. OTHERS
9.11.1. Overview
9.11.2. others Market Forecast and Analysis
10. CHEMOTHERAPY MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. SPECIALTY CENTERS
10.4.1. Overview
10.4.2. Specialty Centers Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. others Market Forecast and Analysis
11. CHEMOTHERAPY MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Chemotherapy Market Overview
11.1.2 North America Chemotherapy Market Forecasts and Analysis
11.1.3 North America Chemotherapy Market Forecasts and Analysis - By Indication
11.1.4 North America Chemotherapy Market Forecasts and Analysis - By Drug Class
11.1.5 North America Chemotherapy Market Forecasts and Analysis - By Route of Administration
11.1.6 North America Chemotherapy Market Forecasts and Analysis - By End User
11.1.7 North America Chemotherapy Market Forecasts and Analysis - By Countries
11.1.7.1 United States Chemotherapy Market
11.1.7.1.1 United States Chemotherapy Market by Indication
11.1.7.1.2 United States Chemotherapy Market by Drug Class
11.1.7.1.3 United States Chemotherapy Market by Route of Administration
11.1.7.1.4 United States Chemotherapy Market by End User
11.1.7.2 Canada Chemotherapy Market
11.1.7.2.1 Canada Chemotherapy Market by Indication
11.1.7.2.2 Canada Chemotherapy Market by Drug Class
11.1.7.2.3 Canada Chemotherapy Market by Route of Administration
11.1.7.2.4 Canada Chemotherapy Market by End User
11.1.7.3 Mexico Chemotherapy Market
11.1.7.3.1 Mexico Chemotherapy Market by Indication
11.1.7.3.2 Mexico Chemotherapy Market by Drug Class
11.1.7.3.3 Mexico Chemotherapy Market by Route of Administration
11.1.7.3.4 Mexico Chemotherapy Market by End User
11.2. EUROPE
11.2.1 Europe Chemotherapy Market Overview
11.2.2 Europe Chemotherapy Market Forecasts and Analysis
11.2.3 Europe Chemotherapy Market Forecasts and Analysis - By Indication
11.2.4 Europe Chemotherapy Market Forecasts and Analysis - By Drug Class
11.2.5 Europe Chemotherapy Market Forecasts and Analysis - By Route of Administration
11.2.6 Europe Chemotherapy Market Forecasts and Analysis - By End User
11.2.7 Europe Chemotherapy Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Chemotherapy Market
11.2.7.1.1 Germany Chemotherapy Market by Indication
11.2.7.1.2 Germany Chemotherapy Market by Drug Class
11.2.7.1.3 Germany Chemotherapy Market by Route of Administration
11.2.7.1.4 Germany Chemotherapy Market by End User
11.2.7.2 France Chemotherapy Market
11.2.7.2.1 France Chemotherapy Market by Indication
11.2.7.2.2 France Chemotherapy Market by Drug Class
11.2.7.2.3 France Chemotherapy Market by Route of Administration
11.2.7.2.4 France Chemotherapy Market by End User
11.2.7.3 Italy Chemotherapy Market
11.2.7.3.1 Italy Chemotherapy Market by Indication
11.2.7.3.2 Italy Chemotherapy Market by Drug Class
11.2.7.3.3 Italy Chemotherapy Market by Route of Administration
11.2.7.3.4 Italy Chemotherapy Market by End User
11.2.7.4 Spain Chemotherapy Market
11.2.7.4.1 Spain Chemotherapy Market by Indication
11.2.7.4.2 Spain Chemotherapy Market by Drug Class
11.2.7.4.3 Spain Chemotherapy Market by Route of Administration
11.2.7.4.4 Spain Chemotherapy Market by End User
11.2.7.5 United Kingdom Chemotherapy Market
11.2.7.5.1 United Kingdom Chemotherapy Market by Indication
11.2.7.5.2 United Kingdom Chemotherapy Market by Drug Class
11.2.7.5.3 United Kingdom Chemotherapy Market by Route of Administration
11.2.7.5.4 United Kingdom Chemotherapy Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Chemotherapy Market Overview
11.3.2 Asia-Pacific Chemotherapy Market Forecasts and Analysis
11.3.3 Asia-Pacific Chemotherapy Market Forecasts and Analysis - By Indication
11.3.4 Asia-Pacific Chemotherapy Market Forecasts and Analysis - By Drug Class
11.3.5 Asia-Pacific Chemotherapy Market Forecasts and Analysis - By Route of Administration
11.3.6 Asia-Pacific Chemotherapy Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Chemotherapy Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Chemotherapy Market
11.3.7.1.1 Australia Chemotherapy Market by Indication
11.3.7.1.2 Australia Chemotherapy Market by Drug Class
11.3.7.1.3 Australia Chemotherapy Market by Route of Administration
11.3.7.1.4 Australia Chemotherapy Market by End User
11.3.7.2 China Chemotherapy Market
11.3.7.2.1 China Chemotherapy Market by Indication
11.3.7.2.2 China Chemotherapy Market by Drug Class
11.3.7.2.3 China Chemotherapy Market by Route of Administration
11.3.7.2.4 China Chemotherapy Market by End User
11.3.7.3 India Chemotherapy Market
11.3.7.3.1 India Chemotherapy Market by Indication
11.3.7.3.2 India Chemotherapy Market by Drug Class
11.3.7.3.3 India Chemotherapy Market by Route of Administration
11.3.7.3.4 India Chemotherapy Market by End User
11.3.7.4 Japan Chemotherapy Market
11.3.7.4.1 Japan Chemotherapy Market by Indication
11.3.7.4.2 Japan Chemotherapy Market by Drug Class
11.3.7.4.3 Japan Chemotherapy Market by Route of Administration
11.3.7.4.4 Japan Chemotherapy Market by End User
11.3.7.5 South Korea Chemotherapy Market
11.3.7.5.1 South Korea Chemotherapy Market by Indication
11.3.7.5.2 South Korea Chemotherapy Market by Drug Class
11.3.7.5.3 South Korea Chemotherapy Market by Route of Administration
11.3.7.5.4 South Korea Chemotherapy Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Chemotherapy Market Overview
11.4.2 Middle East and Africa Chemotherapy Market Forecasts and Analysis
11.4.3 Middle East and Africa Chemotherapy Market Forecasts and Analysis - By Indication
11.4.4 Middle East and Africa Chemotherapy Market Forecasts and Analysis - By Drug Class
11.4.5 Middle East and Africa Chemotherapy Market Forecasts and Analysis - By Route of Administration
11.4.6 Middle East and Africa Chemotherapy Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Chemotherapy Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Chemotherapy Market
11.4.7.1.1 South Africa Chemotherapy Market by Indication
11.4.7.1.2 South Africa Chemotherapy Market by Drug Class
11.4.7.1.3 South Africa Chemotherapy Market by Route of Administration
11.4.7.1.4 South Africa Chemotherapy Market by End User
11.4.7.2 Saudi Arabia Chemotherapy Market
11.4.7.2.1 Saudi Arabia Chemotherapy Market by Indication
11.4.7.2.2 Saudi Arabia Chemotherapy Market by Drug Class
11.4.7.2.3 Saudi Arabia Chemotherapy Market by Route of Administration
11.4.7.2.4 Saudi Arabia Chemotherapy Market by End User
11.4.7.3 U.A.E Chemotherapy Market
11.4.7.3.1 U.A.E Chemotherapy Market by Indication
11.4.7.3.2 U.A.E Chemotherapy Market by Drug Class
11.4.7.3.3 U.A.E Chemotherapy Market by Route of Administration
11.4.7.3.4 U.A.E Chemotherapy Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Chemotherapy Market Overview
11.5.2 South and Central America Chemotherapy Market Forecasts and Analysis
11.5.3 South and Central America Chemotherapy Market Forecasts and Analysis - By Indication
11.5.4 South and Central America Chemotherapy Market Forecasts and Analysis - By Drug Class
11.5.5 South and Central America Chemotherapy Market Forecasts and Analysis - By Route of Administration
11.5.6 South and Central America Chemotherapy Market Forecasts and Analysis - By End User
11.5.7 South and Central America Chemotherapy Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Chemotherapy Market
11.5.7.1.1 Brazil Chemotherapy Market by Indication
11.5.7.1.2 Brazil Chemotherapy Market by Drug Class
11.5.7.1.3 Brazil Chemotherapy Market by Route of Administration
11.5.7.1.4 Brazil Chemotherapy Market by End User
11.5.7.2 Argentina Chemotherapy Market
11.5.7.2.1 Argentina Chemotherapy Market by Indication
11.5.7.2.2 Argentina Chemotherapy Market by Drug Class
11.5.7.2.3 Argentina Chemotherapy Market by Route of Administration
11.5.7.2.4 Argentina Chemotherapy Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CHEMOTHERAPY MARKET, KEY COMPANY PROFILES
13.1. BRISTOL-MYERS SQUIBB COMPANY
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CELGENE CORPORATION
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ELI LILLY AND COMPANY
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. F. HOFFMANN-LA ROCHE LTD
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. GLAXOSMITHKLINE PLC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. JOHNSON AND JOHNSON SERVICES INC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MERCK AND CO. INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. NOVARTIS AG
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. PFIZER INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. SANOFI S.A.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Bristol-Myers Squibb Company
2. Celgene Corporation
3. Eli Lilly and Company
4. F. Hoffmann-La Roche Ltd
5. GlaxoSmithKline PLC
6. Johnson & Johnson Services Inc
7. Merck & Co. Inc.
8. Novartis AG
9. Pfizer Inc.
10. Sanofi S.A.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For